Maturitas
Volume 55 , Pages S75-S82 , 1 November 2006

Inhibition of 5α-reductase in the rat prostate by Cimicifuga racemosa

  • D. Seidlová-Wuttke

      Affiliations

    • Department of Clinical and Experimental Endocrinology, University of Goettingen, Robert-Koch-Strasse 40, D-37075 Göttingen, Germany
    • ,
  • L. Pitzel

      Affiliations

    • Department of Clinical and Experimental Endocrinology, University of Goettingen, Robert-Koch-Strasse 40, D-37075 Göttingen, Germany
    • ,
  • P. Thelen

      Affiliations

    • Department of Urology, University of Goettingen, Germany
    • ,
  • W. Wuttke

      Affiliations

    • Department of Clinical and Experimental Endocrinology, University of Goettingen, Robert-Koch-Strasse 40, D-37075 Göttingen, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 551 396714; fax: +49 551 396518.

References 

  1. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol. 2004;172:1314–1317
  2. Andriole G, Bruchovsky N, Chung LW, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004;172:1399–1403
  3. Borst SE, Lee JH, Conover CF. Inhibition of 5{alpha}-reductase blocks prostate effects of testosterone without blocking anabolic effects. Am J Physiol Endocrinol Metab. 2005;288:E222–E227
  4. Flores E, Bratoeff E, Cabeza M, Ramirez E, Quiroz A, Heuze I. Steroid 5alpha-reductase inhibitors. Mini Rev Med Chem. 2003;3:225–237
  5. Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol. 2002;119:992–1007
  6. Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol. 2002;198:89–95
  7. Gao W, Kearbey JD, Nair VA, et al. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology. 2004;145:5420–5428
  8. Handratta VD, Jelovac D, Long BJ, et al. Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. J Steroid Biochem Mol Biol. 2004;92:155–165
  9. Higgins B, Thompson IM. The prostate cancer prevention trial: current status. J Urol. 2004;171:S15–S17discussion S18
  10. Klein EA, Thompson IM. Update on chemoprevention of prostate cancer. Curr Opin Urol. 2004;14:143–149
  11. Marberger M, Adolfsson J, Borkowski A, et al. The clinical implications of the prostate cancer prevention trial. BJU Int. 2003;92:667–671
  12. Thomas LN, Lazier CB, Gupta R, et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate. 2004;15:231–239
  13. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224
  14. Wang LG, Mencher SK, McCarron JP, Ferrari AC. The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: case report and review. Oncol Rep. 2004;11:1325–1329
  15. Lowe FC, McConnell JD, Hudson PB, et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology. 2003;61:791–796
  16. Jarry H, Thelen P, Christoffel V, Spengler B, Wuttke W. Cimicifuga racemosa extract BNO 1055 inhibits proliferation of the human prostate cancer cell line LNCaP. Phytomedicine. 2005;12(3):178–182
  17. Seidlova-Wuttke D, Jarry H, Pitzel L, Wuttke W. Effects of estradiol-17ß, testosterone and a black cohosh preparation on bone and prostate in orchidectomized rats. Maturitas. 2005;51(2):187–198
  18. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276–308
  19. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 1996;93:5925–5930
  20. Weihua Z, Lathe R, Warner M, Gustafsson JA. An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta, 17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci USA. 2002;99:13589–13594
  21. Weihua Z, Warner M, Gustafsson JA. Estrogen receptor beta in the prostate. Mol Cell Endocrinol. 2002;193:1–5
  22. Imamov O, Morani A, Shim GJ, et al. Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. Proc Natl Acad Sci USA. 2004;101:9375–9380
  23. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev. 2002;23:175–200
  24. Risbridger GP, Bianco JJ, Ellem SJ, McPherson SJ. Oestrogens and prostate cancer. Endocr Relat Cancer. 2003;10:187–191
  25. Gray LE, Ostby J, Wilson V, et al. Xenoendocrine disrupters-tiered screening and testing: filling key data gaps. Toxicology. 2002;181–182:371–382
  26. Gelbke HP, Kayser M, Poole A. OECD test strategies and methods for endocrine disruptors. Toxicology. 2004;205:17–25
  27. Rosen MB, Wilson VS, Schmid JE, Gray LE. Gene expression analysis in the ventral prostate of rats exposed to vinclozolin or procymidone. Reprod Toxicol. 2005;19:367–379
  28. Nellemann C, Dalgaard M, Holst B, Bonefeld-Jorgensen EC, Vinggaard AM. Gene expression changes in rat prostate after activation or blocking of the androgen and estrogen receptor. Mol Cell Endocrinol. 2005;237:25–35
  29. Seidlova-Wuttke D, Jarry H, Pitzel L, Wuttke W. Effects of estradiol-17ß, testosterone and a black cohosh preparation on bone and prostate in orchidectomized rats. Maturitas. 2005;51:177–186
  30. Popp M, Schenk R, Abel G. Cultivation of Cimicifuga racemosa (L.) nuttal and quality of CR extract BNO 1055. Maturitas. 2003;44(Suppl. 1):S1–S7
  31. Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinology. 1999;140:4509–4515
  32. Fitts JM, Klein RM, Powers CA. Comparison of tamoxifen and testosterone propionate in male rats: differential prevention of orchidectomy effects on sex organs, bone mass, growth, and the growth hormone-IGF-I axis. J Androl. 2004;25:523–534
  33. Torring N, Vinter-Jensen L, Pedersen SB, Sorensen FB, Flyvbjerg A, Nexo E. Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate. J Urol. 1997;158:222–227
  34. Yeap BB, Wilce JA, Leedman PJ. The androgen receptor mRNA. Bioessays. 2004;26:672–682
  35. Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res. 2000;60:3175–3182
  36. Liu J, Burdette JE, Xu H, et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem. 2001;49:2472–2479
  37. Zierau O, Bodinet C, Kolba S, Wulf M, Vollmer G. Antiestrogenic activities of Cimicifuga racemosa extracts. J Steroid Biochem Mol Biol. 2002;80:125–130
  38. Wober J, Heinrich K, Scheel B, Vollmer G. Phytoestrogens effects in a human endometrial adenocarcinoma cell line using an estrogen receptor ß (ERß) transactivation system. Paper presented at: the 51st Annual Congress of the Society for Medicinal Plant Research. Germany: Kiel; 2003;
  39. Brunnberg S, Pettersson K, Rydin E, Matthews J, Hanberg A, Pongratz I. The basic helix-loop-helix-PAS protein ARNT functions as a potent coactivator of estrogen receptor-dependent transcription. Proc Natl Acad Sci USA. 2003;100:6517–6522
  40. Safe S, Wormke M, Samudio I. Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells. J Mammary Gland Biol Neoplasia. 2000;5:295–306
  41. Schoenfeld JR, Vasser M, Jhurani P, et al. Distinct molecular phenotypes in murine cardiac muscle development, growth, and hypertrophy. J Mol Cell Cardiol. 1998;30:2269–2280
  42. Chang CS, Kokontis J, Liao ST. Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci USA. 1988;85:7211–7215

PII: S0378-5122(06)00241-6

doi: 10.1016/j.maturitas.2006.06.019

Maturitas
Volume 55 , Pages S75-S82 , 1 November 2006

Article Tools

* Image Usage & Resolution